192
Participants
Start Date
August 8, 2019
Primary Completion Date
April 26, 2022
Study Completion Date
October 27, 2022
Dolutegravir 50 mg
Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a lead-in supplementary dose of 50 mg dolutegravir taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
Placebo
Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a matching placebo taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
Khayelitsha Site B/Ubuntu Community Health Clinic, Cape Town
Wellcome Trust
OTHER
Médecins Sans Frontières, Belgium
OTHER
University of Cape Town
OTHER